Dechra Pharmaceuticals PLC 2018 Annual Financial Report & Notice of Meeting (0483B)
September 18 2018 - 2:30AM
UK Regulatory
TIDMDPH
RNS Number : 0483B
Dechra Pharmaceuticals PLC
18 September 2018
18 September 2018
Dechra(R) Pharmaceuticals PLC
(the Company)
Annual Financial Report
The Company announced its Preliminary Results on 3 September
2018 in accordance with the financial reporting obligations of the
Disclosure and Transparency Rules.
Copies of the Annual Report and Accounts for the year ended 30
June 2018, Notice of Annual General Meeting and Proxy Form have now
been mailed to shareholders.
Copies of the Annual Report and Accounts and Notice of Annual
General Meeting have also been submitted to the National Storage
Mechanism and will shortly be available for inspection at
www.morningstar.co.uk/uk/nsm.
The Annual Report and Accounts, Notice of Annual General
Meeting, proposed Dechra Global Save as You Earn Plan and
information relating to the voting rights of Shareholders (as
required by section 311A of the Companies Act 2006) are available
to view on the Company's website www.dechra.com. Further copies of
the Annual Report and Accounts are available from the Company's
registered office at:
24 Cheshire Avenue
Cheshire Business Park
Lostock Gralam
Northwich
CW9 7UA
Enquiries:
Melanie Hall, Company Secretary
Dechra Pharmaceuticals PLC
Tel: +44 (0) 1606 814730
About Dechra
Dechra is an international specialist veterinary pharmaceuticals
and related products business. Our expertise is in the development,
manufacture, and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products. For more
information please visit: www.dechra.com.
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACSLFFEVAEIDLIT
(END) Dow Jones Newswires
September 18, 2018 03:30 ET (07:30 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2024 to May 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From May 2023 to May 2024